跳转至内容
Merck
CN

Y0001445

塞来昔布

European Pharmacopoeia (EP) Reference Standard

别名:

4- [5-(4-甲基苯基)-3-(三氟甲基)-1H-吡唑-1-基] 苯磺酰胺, CJ-016377, CP-598107, PF-00345549, PHA-00846533, SC-58635, YM-177

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H14F3N3O2S
分子量:
381.37
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

celecoxib

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

Cc1ccc(cc1)-c2cc(nn2-c3ccc(cc3)S(N)(=O)=O)C(F)(F)F

InChI

1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)

InChI key

RZEKVGVHFLEQIL-UHFFFAOYSA-N

基因信息

human ... PTGS2(5743)

正在寻找类似产品? 访问 产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

应用

塞来昔布EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

塞来昔布是一种非甾体类抗炎药 (NSAID) 和环氧化酶-2 (COX-2) 选择性抑制剂。塞来昔布对 COX-2 的选择性至少是 COX-1 的 10-20 倍。

包装

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他说明

可能适用相应的销售限制。

象形图

Health hazardEnvironment

警示用语:

Danger

危险声明

危险分类

Aquatic Chronic 1 - Repr. 1B - STOT RE 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Manon C Zweers et al.
Arthritis research & therapy, 13(5), 239-239 (2011-10-01)
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, and synovial inflammation, causing substantial physical disability, impaired quality of life, and significant health care utilization. Traditionally, non-steroidal anti-inflammatory drugs (NSAIDs)
Leyte L Winfield et al.
Future medicinal chemistry, 4(3), 361-383 (2012-03-08)
Celecoxib is a multifaceted drug with promising anticancer properties. A number of studies have been conducted that implicate the compound in modulating the expression of Bcl-2 family members and mitochondria-mediated apoptosis. The growing data surrounding the role of celecoxib in
Marta Garcia et al.
BJU international, 113(5b), E164-E177 (2013-10-17)
To assess whether celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor with anti-cancer properties, has an inhibitory effect on tumour establishment and progression of prostate cancer (PCa) bone metastases. PC-3 stable luciferase-expressing cells were injected into male nude mice by intracardiac (i.c.)
Verena Jendrossek
Cancer letters, 332(2), 313-324 (2011-02-25)
Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor types, such as colorectal, breast, non-small cell lung, and prostate cancers. Up to now, the drug
Axel H Schönthal et al.
Expert opinion on investigational drugs, 17(2), 197-208 (2008-01-31)
Celecoxib is an NSAID that was developed as a selective inhibitor of COX-2 and approved by the FDA for the treatment of various forms of arthritis and the management of acute or chronic pain. In addition, it was more recently

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门